Phase I study of GTI-2040, a ribonucleotide reductase antisense, with high dose cytarabine in patients with relapsed/refractory acute myeloid leukemia

References

• Dai G, Chan KK, Liu S, et al. Cellular uptake and intracellular levels of the bcl-2 antisense g3139 in cultured cells and treated patients with acute myeloid leukemia. Clin Cancer Res 2005;11:2998–3008.
   Google Scholar
• Litzow MR, Othus M, Cripe LD, et al. Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group. Br J Haematol 2010;148:217–225.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Stock W, Dai G, et al. G3139, a BCL-2 antisense oligo-nucleotide, in AML. Ann Hematol 2004;83(Suppl. 1):S93–S94.
   PubMedGoogle Scholar
• Marcucci G, Byrd JC, Dai G, et al. Phase 1 and pharmacodynamic studies of G3139, a Bcl-2 antisense oligonucleotide, in combination with chemotherapy in refractory or relapsed acute leukemia. Blood 2003;101:425–432.
   PubMed Web of Science ®Google Scholar
• Chemnitz JM, von Lilienfeld-Toal M, Holtick U, et al. Intermediate intensity conditioning regimen containing FLAMSA, treosulfan, cyclophosphamide, and ATG for allogeneic stem cell transplantation in elderly patients with relapsed or high-risk acute myeloid leukemia. Ann Hematol 2012;91:47–55.
   PubMed Web of Science ®Google Scholar
• Galmarini CM, Mackey JR, Dumontet C. Nucleoside analogues: mechanisms of drug resistance and reversal strategies. Leukemia 2001;15:875–890.
   PubMed Web of Science ®Google Scholar
• Estey EH. Treatment of relapsed and refractory acute myelogenous leukemia. Leukemia 2000;14:476–479.
   PubMed Web of Science ®Google Scholar
• Kimby E, Nygren P, Glimelius B. A systematic overview of chemotherapy effects in acute myeloid leukaemia. Acta Oncol 2001;40:231–252.
   PubMed Web of Science ®Google Scholar
• Estey E, Thall P, Andreeff M, et al. Use of granulocyte colony-stimulating factor before, during, and after fludarabine plus cytarabine induction therapy of newly diagnosed acute myelogenous leukemia or myelodysplastic syndromes:comparison with fludarabine plus cytarabine without granulocyte colony-stimulating factor. J Clin Oncol 1994;12:671–678.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Plunkett W. Modulation of arabinosylnucleoside metabolism by arabinosylnucleotides in human leukemia cells. Cancer Res 1988;48:329–334.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Estey E, Keating MJ, et al. Fludarabine potentiates metabolism of cytarabine in patients with acute myelogenous leukemia during therapy. J Clin Oncol 1993;11:116–124.
   PubMed Web of Science ®Google Scholar
• Gandhi V, Estey E, Du M, et al. Modulation of the cellular metabolism of cytarabine and fludarabine by granulocyte-colony-stimulating factor during therapy of acute myelogenous leukemia. Clin Cancer Res 1995;1:169–178.
   PubMed Web of Science ®Google Scholar
• Yee KW, Cortes J, Ferrajoli A, et al. Triapine and cytarabine is an active combination in patients with acute leukemia or myelodysplastic syndrome. Leuk Res 2006;30:813–822.
   PubMed Web of Science ®Google Scholar
• Fan H, Villegas C, Wright JA. Ribonucleotide reductase R2 component is a novel malignancy determinant that cooperates with activated oncogenes to determine transformation and malignant potential. Proc Natl Acad Sci USA 1996;93:14036–14040.
   PubMed Web of Science ®Google Scholar
• Fan H, Villegas C, Huang A, et al. The mammalian ribonucleotide reductase R2 component cooperates with a variety of oncogenes in mechanisms of cellular transformation. Cancer Res 1998;58:1650–1653.
   PubMed Web of Science ®Google Scholar
• Fukushima M, Fujioka A, Uchida J, et al. Thymidylate synthase (TS) and ribonucleotide reductase (RNR) may be involved in acquired resistance to 5-fluorouracil (5-FU) in human cancer xenografts in vivo. Eur J Cancer 2001;37:1681–1687.
   Google Scholar
• Iwasaki H, Huang P, Keating MJ, et al. Differential incorporation of ara-C, gemcitabine, and fludarabine into replicating and repairing DNA in proliferating human leukemia cells. Blood 1997; 90:270–278.
   PubMed Web of Science ®Google Scholar
• Kubota T, Watanabe M, Otani Y, et al. Different pathways of 5-fluorouracil metabolism after continuous venous or bolus injection in patients with colon carcinoma: possible predictive value of thymidylate synthetase mRNA and ribonucleotide reductase for 5-fluorouracil sensitivity. Anticancer Res 2002;22:3537–3540.
   PubMed Web of Science ®Google Scholar
• Mansson E, Spasokoukotskaja T, Sallstrom J, et al. Molecular and biochemical mechanisms of fludarabine and cladribine resistance in a human promyelocytic cell line. Cancer Res 1999;59:5956–5963.
   PubMed Web of Science ®Google Scholar
• Matsusaka S, Yamasaki H, Fukushima M, et al. Upregulation of enzymes metabolizing 5-fluorouracil in colorectal cancer. Chemotherapy 2007;53:36–41.
   PubMed Web of Science ®Google Scholar
• Okamura H, Kamei T, Sakuma N, et al. Ribonucleotide reductase immunoreactivity in adenocarcinoma cells and malignant or reactive mesothelial cells in serous effusions. Acta Cytol 2003;47:209–215.
   PubMed Web of Science ®Google Scholar
• Agarwal N, Gewirtz AM. Oligonucleotide therapeutics for hematologic disorders. Biochim Biophys Acta 1999;1489:85–96.
   PubMed Web of Science ®Google Scholar
• Gewirtz AM. Antisense oligonucleotide therapeutics for human leukemia. Curr Opin Hematol 1998;5:59–71.
   PubMedGoogle Scholar
• Marcucci G, Caligiuri MA. Antisense and gene transfer as therapeutic strategies in acute and chronic leukemia. In: Henderson EA, editor. Leukemia. 7th ed. New York: WB Saunders; 2002. pp. 449–457.
   Google Scholar
• Cheson BD, Cassileth PA, Head DR, et al. Report of the National Cancer Institute-sponsored workshop on definitions of diagnosis and response in acute myeloid leukemia. J Clin Oncol 1990;8:813–819.
   PubMed Web of Science ®Google Scholar
• Marcucci G, Stock W, Dai G, et al. Phase I study of oblimersen sodium, an antisense to Bcl-2, in untreated older patients with acute myeloid leukemia: pharmacokinetics, pharmacodynamics, and clinical activity. J Clin Oncol 2005;23:3404–3411.
   PubMed Web of Science ®Google Scholar
• Wei X, Dai G, Marcucci G, et al. A specific picomolar hybridization-based ELISA assay for the determination of phosphorothioate oligonucleotides in plasma and cellular matrices. Pharm Res 2006;23: 1251–1264.
   PubMed Web of Science ®Google Scholar
• Klisovic RB, Blum W, Wei X et al. Phase I study of GTI-2040, an antisense to ribonucleotide reductase, in combination with high-dose cytarabine in patients with acute myeloid leukemia. Clin Cancer Res 2008;14:3889–3895.
   PubMed Web of Science ®Google Scholar
• Chen P, Liu Z, Liu S, et al. A LC-MS/MS method for the analysis of intracellular nucleoside triphosphate levels. Pharm Res 2009;26: 1504–1515.
   PubMed Web of Science ®Google Scholar